Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of inactivated mycoplasma synoviae vaccine

A technology of mycoplasma synovialum and inactivated vaccines, which is applied in the direction of emulsion delivery, bacterial antigen components, bacteria, etc., can solve the problems of inability to eliminate MS infection in chicken flocks, easy to produce drug resistance, and no vaccines on the market. The effect of reducing production cost, simplifying production process and increasing output

Active Publication Date: 2014-01-08
兆丰华生物科技(南京)有限公司
View PDF7 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In vitro tests have shown that MS is sensitive to certain antibiotics, including oxytetracycline, enrofloxacin, lincomycin, riscomycin, tetracycline, tylosin, tilmicosin, etc., but MS is prone to develop resistance. Therefore, drug control should first pay attention to intermittent drug use, drug rotation and screening of sensitive drugs to avoid the emergence of drug resistance, and secondly, antibiotic therapy cannot clear MS infection in chicken flocks; therefore, immunization is a more effective measure to control the disease
Vaccine immunization has been proved to be effective in controlling the disease in foreign related trials, and has been widely used in Australia, but there is no successful vaccine on the market in China

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] 1 Prepare culture medium

[0024] From September 21st to 22nd, 2008, 3000 ml of basal culture medium for Mycoplasma gallinarum was prepared. Weigh 84g of PPLO broth, 28g of hydrolyzed milk protein, 12g of yeast extract powder, 1.2g of nicotinamide, 8ml of phenol red solution with a mass concentration of 0.4%, and 3000ml of deionized water, mix and autoclave at 121°C for 15 minutes.

[0025] The finished medium is to add about 20% pig serum and 1000 units / ml penicillin to the basic medium, adjust the pH to 7.7 with 20% NaOH, and store it at 4°C for later use.

[0026] 2 The cultivation of mycoplasma synovial bursae bacterium liquid and the preparation of inactivated vaccine:

[0027] (1) Propagation of secondary seed liquid of Mycoplasma gallinae: inoculate Mycoplasma gallinarum HN01 strain in the finished product culture medium of Mycoplasma gallinabilis at a ratio of 1:10, culture at 37°C for 48 hours, and the pH value of the culture Dropped to 6.6, harvested as the ...

Embodiment 2

[0042] 1 Preparation of medium

[0043]From April 12th to 13th, 2009, 5250 ml of mycoplasma basal medium was prepared. Weigh 147g of PPLO broth, 42g of hydrolyzed milk protein, 28g of yeast extract powder, 2.1g of nicotinamide, 14ml of phenol red solution with a mass concentration of 0.4%, and 5250ml of deionized water, mix and autoclave at 121°C for 15 minutes.

[0044] The finished medium is to add about 20% pig serum and 1000 units / ml penicillin to the basic medium, adjust the pH to 7.8 with 20% NaOH, and store it at 4°C for later use.

[0045] 2 Culture of mycoplasma synovialum bacteria liquid and preparation of inactivated vaccine:

[0046] (1) Propagation of secondary seed liquid of Mycoplasma gallinae: inoculate Mycoplasma gallinarum HN01 strain in the finished product culture medium of Mycoplasma gallinabilis at a ratio of 1:10, culture at 37°C for 48 hours, and the pH value of the culture Dropped to 6.5, harvested as the first-level seed liquid; in the same way, the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method of an inactivated mycoplasma synoviae vaccine. The vaccine provided by the invention is prepared by the following steps of inoculating a mycoplasma synoviae HN01 strain with good immunogenicity to a proper culture medium, harvesting cultures, inactivating the cultures by utilizing a formaldehyde solution, and adding an adjuvant to carry out mixing and emulsification. The vaccine is used for preventing the mycoplasma synovial and has the advantages of good security, high immune efficacy and the like.

Description

technical field [0001] The invention belongs to the technical field of veterinary biological products, and more specifically relates to a preparation method of an inactivated vaccine of mycoplasma synovialis. Background technique [0002] Mycoplasma gallinarum is one of the most important pathogenic bacteria in Mycoplasma avium. It can infect chickens and turkeys. It mainly causes joint exudative synovial meningitis and tenosynovitis, which is highly contagious. , and often mixed with bacteria or viruses to cause disease, causing huge economic losses to the chicken industry. Prevention and treatment of MS mainly adopts drug therapy and immunization. In vitro tests have shown that MS is sensitive to certain antibiotics, including oxytetracycline, enrofloxacin, lincomycin, riscomycin, tetracycline, tylosin, tilmicosin, etc., but MS is prone to develop resistance. Therefore, drug control must first pay attention to intermittent drug use, drug rotation and screening of sen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/02A61K9/107A61P31/04C12N1/20
Inventor 丁美娟尹秀凤汪爱芬
Owner 兆丰华生物科技(南京)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com